[ad_1] PROVIDENCE, R.I., Dec. 6, 2024 /PRNewswire/ — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth. This […]

[ad_1] PROVIDENCE, R.I., Dec. 6, 2024 /PRNewswire/ — EpiVax, a leader in biotechnology known for its advanced immunoinformatics tools, proudly announces its continued support for two nonprofits, Clínica Esperanza/Hope Clinic and GAIA Vaccine Foundation. EpiVax supports these […]